Paul J Balderes from 200 Cabrini Blvd APT 54, New York, NY 10033, age 65, Phone: 212 781-0417

Paul Balderes Phones & Addresses

200 Cabrini Blvd APT 54, New York, NY 10033 • 212 781-0417
Wappingers Falls, NY
200 Cabrini Blvd APT 54, New York, NY 10033

Work

Company:

Tri-tdi
Oct 2017
Position:

Director biologics discovery

Education

Degree:

Graduate or professional degree

Skills

Drug Discovery • Monoclonal Antibodies • Assay Development • Protein Chemistry • Antibodies • Drug Development • Protein Purification • Cancer Research • Immunology • Biopharmaceuticals • Cell • Purification • In Vitro • Biotechnology • Elisa • Biochemistry • Clinical Development

Industries

Biotechnology

Us Patents

Anti-Tyrp1 Antibodies
view source
US Patent:

20090232823, Sep 17, 2009
Filed:

Mar 11, 2009
Appl. No.:

12/401800
Inventors:

Paul J. Balderes - New York NY, US
Xiaoqiang Kang - Plainsboro NJ, US
International Classification:

A61K 39/395
C07K 16/18
C12N 15/13
C12N 15/63
C12P 21/08
A61P 35/00
C12N 5/10
C12N 1/19
C12N 1/15
C12N 1/21
US Classification:

4241391, 5303879, 536 2353, 4353201, 435 696, 435325, 435354, 435358, 4352542, 43525411, 43525233, 43525231
Abstract:

The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment.

Resumes

Director Biologics Discovery

view source

Location:

New York, NY

Industry:

Biotechnology

Work:

Tri-Tdi
Director Biologics Discovery
Eli Lilly and Company Nov 1, 2011 - May 2017
Antibody Drug Conjugate Program Director
Eli Lilly and Company Jan 2011 - May 2017
Director of Biologics Technology
Imclone Systems, A Wholly-Owned Subsidiary of Eli Lilly and Company Jan 1, 2009 - Dec 1, 2010
Associate Director, Protein Science
Imclone Systems, A Wholly-Owned Subsidiary of Eli Lilly and Company Jan 1, 2007 - Dec 1, 2008
Senior Group Leader, Protein Chemistry

Skills:

Drug Discovery
Monoclonal Antibodies
Assay Development
Protein Chemistry
Antibodies
Drug Development
Protein Purification
Cancer Research
Immunology
Biopharmaceuticals
Cell
Purification
In Vitro
Biotechnology
Elisa
Biochemistry
Clinical Development

Paul J Balderes